UBS’s Northwest Biotherapeutics, Inc. NWBOW Stock Holding History

UBS’s Portfolio NWBOW Stock Details NWBOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2,732	Closed	-$10K	–	11377
2014 Q2	$10K	Buy	2,732 +2,574	+1,629%	+$10.2K	﹤0.01%	8945
2014 Q1	$1K	Buy	+158	New	+$584	﹤0.01%	10328
2013 Q3	–	Sell	-100	Closed	–	–	11274
2013 Q2	$0	Buy	+100	New	+$201	﹤0.01%	10241

Other funds holding NWBOW

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

UBS's NWBOW Position: Q3 2014 in Review

UBS sold out of Northwest Biotherapeutics, Inc. (NWBOW) in Q3 2014, closing a stake of 2,732 shares — an estimated $10K sold.

UBS first reported a position in NWBOW in Q2 2013 and held it in 3 quarters. The position peaked at $10K in Q2 2014. 2 funds tracked by Wall St. Rank hold NWBOW as of Q3 2014.

UBS reported no remaining Northwest Biotherapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
UBS sold 2,732 Northwest Biotherapeutics, Inc. shares in Q3 2014, an estimated $10K.
UBS first reported a position in Northwest Biotherapeutics, Inc. in Q2 2013 and held it in 3 quarters.
UBS's Northwest Biotherapeutics, Inc. position peaked at $10K in Q2 2014.
2 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.